Newsletter Banner

  Fall 2014 Volume 5, Issue 4  

 



Bookmark and Share
Start a Free Trial Button

In This Issue
Get the NRC Update Newsletter!
Join Our Mailing List
Recently Updated Topics

  • Anemia: an Overview
  • Cesarean Section, Repeat
  • Fetal Alcohol Syndrome
  • Melanoma
  • Stroke: an Overview
  • Trisomy 13 (Patau Syndrome)
  • Cervical Cancer: Staging
  • Alcohol Withdrawal Syndrome
  • Meconium Aspiration Syndrome
  • Melanoma: Disease Staging
  • And much more!
     

  • Quick Links

    Nursing Reference Center Peer Review
    Become a

    Related Resources

    Dynamed

     

    Patient Education Reference Center 

     

    Rehabilitation Reference Center

    Welcome!
    Welcome back to our free evidence-based Nursing Reference Center Update. We will periodically send news on the latest evidence in nursing. Please share this with your colleagues, students, practitioners and others who would appreciate awareness of this information. 
    Nursing Reference Center in Daily Practice

    Autonomic Dysreflexia

     

    Mrs. A is a 62 year old woman with a recent thoracic spinal cord injury who is currently being treated in the rehabilitation unit. The nurse knows that Mrs. A is at risk of autonomic dysreflexia. The nurse wants to learn more about autonomic dysreflexia so she consults Nursing Reference Center, keying in autonomic dysreflexia. She consults the quick lesson "Autonomic Dysreflexia."

    The nurse reads about autonomic dysreflexia, including signs and symptoms, treatment goals, and red flags. Based on the information in the quick lesson, the nurse assesses Mrs. A's vital signs and for the cause of autonomic dysreflexia, removing the trigger if possible. The nurse checks the urinary catheter for kinks and obstructions and irrigates the bladder if necessary. She educates Mrs. A about the potential complications, treatment risks and benefits, and individualized prognosis
    .


    Note: The above referenced Quick Lesson is freely accessible to all readers of the Nursing Reference Center Update. 

    Quick Overview

    Caring for Patients with Blau Syndrome (BS)

     

    Blau syndrome (BS) is a rare and chronic inflammatory disorder inherited in an autosomal dominant manner that is characterized by the childhood appearance of polyarthritis, rash, and uveitis. BS is caused by mutations in the NOD2 (also known as CARD15) gene. BS can present in a typical or atypical manner. Signs and symptoms of typical BS include granulomatous (i.e., localized nodular inflammation of granuloma tissue) polyarthritis, synovitis (i.e., inflammation of the lining of the joints), synovial cysts, a skin rash of erythematous, raised lesions with fine scales, and uveitis (i.e., inflammation of the uveal tract, which lines the inside of the eye behind the cornea). In addition to the signs and symptoms of typical BS, atypical BS affects additional organs and body systems such as the kidneys, liver, and/or peripheral nerves (e.g., causing cranial neuropathies).

     

    Onset of BS is usually before 5 years of age and has been reported as early as 4 months of age. The first manifestation of either type of BS is usually a rash. Contractures from arthritis can develop as a potential medical complication of BS, and uveitis can result in elevated intraocular pressure (IOP), leading to vision loss. Other potential complications of uveitis include cataracts, detached retina, and glaucoma. Diagnosis of BS is confirmed by skin, synovial, or conjunctival biopsy and/or by genetic testing. 


    There are no reports of randomized clinical trials on the management of BS. Current clinical treatment of BS focuses on relief of symptoms and includes corticosteroids (e.g., prednisone, prednisolone acetate suspension) and anti-inflammatory medications (e.g., methotrexate; infliximab, [a tumor necrosis factor (TNF)-alpha inhibitor]; cyclosporine A) to allow for reduced corticosteroid dosage. Topical drugs for uveitis include corticosteroids to suppress inflammation and cycloplegics (i.e., drugs that cause paralysis of the ciliary muscles of the eye; e.g., atropine sulphate 1%, homatropine). Eye surgery may be required to treat complications of uveitis. When treatment of uveitis is prompt, the condition usually subsides within days or weeks; however, uveitis frequently recurs.

     

    Please login to your Nursing Reference Center subscription to read the Quick Lesson on "Blau Syndrome."

    Evidence-based Content Update

    Recently, the evidence-based care sheet "Behçet's Syndrome" was revised following review under the systematic literature surveillance program. Information of value to nursing practice regarding Behçet's syndrome was a research study. The International Team for the Revision of the International Criteria for Behçet's Disease proposed new diagnostic criteria. Ocular lesions, oral aphthosis, and genital aphthosis are each assigned 2 points; skin lesions, CNS involvement, and vascular manifestations are given 1 point each. Positive pathergy test is assigned 1 point. BS is diagnosed in patients with ≥ 4 points. The new diagnostic criteria demonstrated higher sensitivity than the ISG criteria (94.8% vs. 85.0%), but lower specificity (90.5% vs. 96.0%).

     

    We invite you to login to the Nursing Reference Center to read updated content as it becomes available.